Botulinum toxin type A for prophylactic treatment of chronic migraine


Record Status
This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' conclusions
It is uncertain whether BTX reduces the frequency of headache days, reduces acute headache pain medication, or has any impact on functioning in comparison with saline. Botulin toxin A injection may result in little or no difference in the number of headache episodes, headache hours and quality of life in comparison to saline injections. It cannot be excluded that saline injections per se have beneficial effects on chronic migraine. The effects of repeated BTX injections during more than one year follow-up are not known.

Final publication URL

Additional data URL
http://www.sahlgrenska.se/sv/SU/Forskning/HTA-centrum/Hogerkolumn-undersidor/Publicerade-rapporter/

Indexing Status
Subject indexing assigned by CRD

MeSH
Humans; Botulinum Toxins, Type A; Migraine Disorders; Neuromuscular Agents

Language Published
English

Country of organisation
Sweden

English summary
An English language summary is available.

Address for correspondence
The Regional Health Technology Assessment Centre, Region Vastra Gotaland, HTA-centrum, Roda Straket 8, Sahlgrenska Universitetssjukhuset, 413 45 GOTHENBORG, Sweden Email: hta-centrum@vgregion.se

AccessionNumber
32016000590

Date abstract record published
29/03/2016